SILENCE THERAPEUTICS PLC-ADR (SLN) Stock Price & Overview
NASDAQ:SLN • US82686Q1013
Current stock price
The current stock price of SLN is 6.17 USD. Today SLN is down by -3.29%. In the past month the price increased by 23.4%. In the past year, price increased by 73.31%.
SLN Key Statistics
- Market Cap
- 291.433M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
SLN Stock Performance
SLN Stock Chart
SLN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SLN. When comparing the yearly performance of all stocks, SLN is one of the better performing stocks in the market, outperforming 90.11% of all stocks.
SLN Earnings
SLN Forecast & Estimates
SLN Groups
Sector & Classification
SLN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SLN Ownership
SLN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.82 | 364.65B | ||
| AMGN | AMGEN INC | 15.24 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.68 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.84 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.29 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.55 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SLN
Company Profile
Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The firm leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The firm focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Company Info
IPO: 2010-01-05
SILENCE THERAPEUTICS PLC-ADR
72 Hammersmith Road
London W14 8TH GB
CEO: Mark Rothera
Employees: 88
Phone: 442034576900
SILENCE THERAPEUTICS PLC-ADR / SLN FAQ
What does SLN do?
Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The firm leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The firm focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
What is the stock price of SILENCE THERAPEUTICS PLC-ADR today?
The current stock price of SLN is 6.17 USD. The price decreased by -3.29% in the last trading session.
Does SILENCE THERAPEUTICS PLC-ADR pay dividends?
SLN does not pay a dividend.
What is the ChartMill rating of SILENCE THERAPEUTICS PLC-ADR stock?
SLN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Who owns SILENCE THERAPEUTICS PLC-ADR?
You can find the ownership structure of SILENCE THERAPEUTICS PLC-ADR (SLN) on the Ownership tab.